Microbot Medical Inc. announced on August 20, 2025, that the United States Patent and Trademark Office (USPTO) has granted the company a patent. This patent covers a modular robotic surgical system, which includes a base and multiple tool-receiver units arranged as separate, independently, and interchangeably attachable units.
The company considers this patent issuance significant as it could enable the LIBERTY system to be adapted in the future for a wider range of endovascular procedures. This expansion would substantially increase the total addressable market Microbot Medical aims to penetrate.
This patent expands the company’s intellectual property protection in the United States for its LIBERTY system portfolio, which now includes 12 patents granted globally and 57 patent applications pending. Microbot Medical believes this could expand its reach to over 6 million annual endovascular procedures in the U.S. alone, up from an estimated 2.5 million peripheral endovascular procedures annually.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.